Patients aged 15 years or older, given a diagnosis of MRSA infection and treated with an anti-MRSA drug (VCM, TEIC, ABK, LZD, or DAP)

n = 684

Excluded patients, n = 319

- Prescription of an anti-MRSA drug during the baseline period (30 days) was recorded or unknown, n = 214
- The period of anti-MRSA drug prescription was less than 2 days: n = 64
- Patients only with a diagnosis of MRCNS, n = 0
- Patients only with a diagnosis of MRSA carrier, n = 4
- Others (Failure to specify the hospitalization date, n = 12; Prescription of two or more anti-MRSA drugs at the beginning of tracing, n = 18; Diagnosis of MRSA infection in several organs, n = 11; Missing data of the dose of an anti-MRSA drug, n = 1) (Patients with multiple reasons for exclusion were counted once for each reason)

Subjects for analysis, n = 365 (bacteremia, n = 120; pneumonia, n = 88; surgical site infection, n = 23; others\*, n = 32; and unknown, n = 102).

\* Other MRSA organs included bone (n = 8), digestive organs (n = 6), respiratory organs other than pneumonia (n = 7), urinary tract (n = 1) and skin (n = 3).

Supplementary Figure 1. Flow-chart of patient selection.

ABK: arbekacin; DAP: daptomycin; LZD: linezolid; MRCNS: methicillin-resistant coagulase-negative Staphylococci, MRSA: methicillin-resistant Staphylococcus aureus; SD: standard deviation; TEIC: teicoplanin; VCM: vancomycin.